This patent is part of Tobira’s portfolio of medicines to treat infectious diseases. In addition, the company recently received a European patent for TBR-220, a second CCR5 antagonist for the treatment of HIV/AIDS.
James Sapirstein, CEO of Tobira Therapeutics, said: “It is gratifying to progress the intellectual property of these compounds and look forward to future clinical trial results.”